PIK3CD and cancer: In 2011, Wu et al [82] synthesized a series of novel 2-arylamino-3-(arylsulfonyl)quinoxalines (238) through a newly developed approach from XL-765 (236, PI3K α/β/δ/γ IC50=39/113/43 /9 nM ) and XL-147 (237, PI3K α/β/δ/γ IC50 = 39/383/36 /23 nM).The most potent compound (239, PI3Kα IC50 = 0.07 μM) validated the potential of 2-arylamino- 3- (arylsulfonyl) quinoxaline series for cancer treatment by targeting PI3Kα.